Views & Analysis 2016 saw slump in FDA drug approvals, but 2017 could be retu... After a lacklustre 2016, FDA approvals could rebound in 2017 - but concerns about big pharma R&D productivity won't go away, writes Craig Sharp
Views & Analysis After 2015's ‘breakthrough’ year for pharma approvals, will ... A look ahead to what major new innovative drugs are expected to gain approval in 2016 and beyond. Andrew McConaghie reports.
Articles 10 drugs – and their prices – which changed pharma in 2015 The FDA approved a total of 45 new drugs this year, the second year in a row the total has risen significantly.
News Clinical trial go-between Inato raises $20m Inato has raised $20 million in early-stage financing to support the continued development of its clinical trial marketplace, which connects sponsors with its network of t
R&D Sponsored Trials and tribulations of drug development What does it take to establish new treatments for rare diseases?